公司概述
Tango Therapeutics, Inc. operates as a precision oncology company dedicated to the discovery and development of drugs within defined patient populations that address significant unmet medical needs. The company functions within the healthcare sector, specifically the biotechnology industry, which focuses on the creation of novel therapeutic agents to treat complex diseases such as cancer. Tango Therapeutics, Inc. currently holds a market capitalization of $2.86 billion and reports an annual revenue of $62.38 million, supported by an organizational structure of 137 employees. The market capitalization of $2.86 billion indicates that the market values the company's pipeline of methylthioadenosine-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, at a scale that suggests substantial potential, while the revenue of $62.38 million reflects the current commercial output from its existing product portfolio.
财务健康
The company reported a revenue of $62.38 million for the trailing twelve months (TTM), yet it recorded a net income of -$101,594,000 and an EBITDA of -$109,008,000, revealing a cost structure where expenses significantly exceed gross revenue generation. The free cash flow stands at -$60,859,624, which indicates that the company is currently burning cash and lacks immediate financial flexibility to fund operations without external capital infusion. Analysis of the three primary margins shows a gross margin of -111.9%, an operating margin of -178.4%, and a profit margin of -162.9%, all of which indicate that the company is incurring losses across all levels of profitability before reaching the bottom line. The balance sheet holds $343.14 million in cash against $33.57 million in debt, resulting in a debt-to-equity ratio of 9.70, which suggests a highly leveraged position relative to equity despite the absolute dollar amount of cash available. The current ratio is listed at 16.32, indicating an extremely high level of short-term liquidity where current assets vastly exceed current liabilities. Return on Equity is -37.2% and Return on Assets is -19.5%, metrics that reveal management is currently generating negative returns on both shareholders' equity and the total asset base.
估值评估
The trailing P/E ratio is listed as N/A due to the absence of positive net income, while the forward P/E is -12.58, implying that the market is pricing in future earnings expectations that have not yet materialized in historical results. The price-to-book ratio is 7.88, indicating that the market values the company at a significant premium over its net asset book value, likely reflecting the high valuation placed on its intellectual property and drug pipeline. The price-to-sales ratio is 45.88 and the EV/EBITDA is -23.42, suggesting that traditional earnings-based valuation models are not applicable and that valuation relies heavily on sales multiples and the potential for future profitability. The stock's 52-week high is $22.20 and the 52-week low is $1.03, placing the current trading environment within a highly volatile range defined by these historical extremes. The beta value is 1.31, meaning the stock price exhibits volatility that is 31% higher than the broader market benchmark.
Growth & Income
The revenue growth year-over-year is -100.0%, while earnings growth year-over-year is N/A, indicating a complete contraction in reported revenue and the absence of a positive earnings trajectory to compare against revenue changes. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all available cash is retained within the company rather than distributed to shareholders. Since the company is not a dividend payer, it reinvests its remaining resources into research and development to advance its PRMT5 inhibitors rather than providing income to investors. The overall growth and income profile is characterized by a total absence of current earnings growth and a zero-dividend policy, relying entirely on capital markets for future expansion and operational sustenance.